|
Leader
|
|
|
00000nz a2200037n 45 0 |
|
001
|
|
|
WKP|Q56952198
(VIAF cluster)
(Authority/Source Record)
|
|
003
|
|
|
WKP |
|
005
|
|
|
20241121000221.0 |
|
008
|
|
|
241121nneanz||abbn n and d |
|
035
|
|
|
‡a
(WKP)Q56952198
|
|
024
|
|
|
‡a
0000-0001-9043-2621
‡2
orcid
|
|
035
|
|
|
‡a
(OCoLC)Q56952198
|
|
100
|
0 |
|
‡a
David E Jones
‡9
es
‡9
ast
|
|
375
|
|
|
‡a
1
‡2
iso5218
|
|
400
|
0 |
|
‡a
ডেভিড ই জোন্স
‡9
bn
|
|
400
|
0 |
|
‡a
David E. Jones
‡c
neurology researcher at University of Virginia Health System
‡9
en
|
|
400
|
0 |
|
‡a
David E Jones
‡c
onderzoeker
‡9
nl
|
|
670
|
|
|
‡a
Author's A Framework of Care in Multiple Sclerosis, Part 2: Symptomatic Care and Beyond
|
|
670
|
|
|
‡a
Author's Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis: a review of its clinical pharmacology, efficacy and safety
|
|
670
|
|
|
‡a
Author's CME/CNE Article: A Framework of Care in Multiple Sclerosis, Part 1: Updated Disease Classification and Disease-Modifying Therapy Use in Specific Circumstances
|
|
670
|
|
|
‡a
Author's Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
|
|
670
|
|
|
‡a
Author's Correction to: The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations.
|
|
670
|
|
|
‡a
Author's Cryptococcal meningitis after fingolimod discontinuation in a patient with multiple sclerosis
|
|
670
|
|
|
‡a
Author's Disease-modifying therapies for nonrelapsing multiple sclerosis: Costs and benefits of medical intervention
|
|
670
|
|
|
‡a
Author's Early Relapsing Multiple Sclerosis
|
|
670
|
|
|
‡a
Author's Evaluation of a Novel Preference Assessment Tool for Patients with Multiple Sclerosis
|
|
670
|
|
|
‡a
Author's Expanding spectrum of opportunistic infections associated with dimethyl fumarate
|
|
670
|
|
|
‡a
Author's Identification and validation of clinically meaningful benchmarks in the 12-item Multiple Sclerosis Walking Scale
|
|
670
|
|
|
‡a
Author's Intramedullary spinal cord metastasis from salivary ductal carcinoma of the parotid gland mimicking transverse myelitis in a patient with radiologically isolated syndrome
|
|
670
|
|
|
‡a
Author's Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis
|
|
670
|
|
|
‡a
Author's Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
|
|
670
|
|
|
‡a
Author's Rehabilitation in multiple sclerosis: Commentary on the recent AAN systematic review
|
|
670
|
|
|
‡a
Author's Splenic marginal zone lymphoma: An indolent malignancy leading to the development of neurolymphomatosis
|
|
670
|
|
|
‡a
Author's Summary of comprehensive systematic review: Rehabilitation in multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology
|
|
670
|
|
|
‡a
Author's The American Academy of Neurology's top five Choosing Wisely recommendations
|
|
670
|
|
|
‡a
Author's The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations
|
|
670
|
|
|
‡a
Author's The state of multiple sclerosis: current insight into the patient/health care provider relationship, treatment challenges, and satisfaction
|
|
909
|
|
|
‡a
(orcid) 0000000190432621
‡9
1
|
|
919
|
|
|
‡a
frameworkofcareinmultiplesclerosispart2symptomaticcareandbeyond
‡A
A Framework of Care in Multiple Sclerosis, Part 2: Symptomatic Care and Beyond
‡9
1
|
|
919
|
|
|
‡a
alemtuzumabforthetreatmentofrelapsingremittingmultiplesclerosisareviewofitsclinic Alpha rmacologyefficacyandsafety
‡A
Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis: a review of its clinical pharmacology, efficacy and safety
‡9
1
|
|
919
|
|
|
‡a
cmecnearticleaframeworkofcareinmultiplesclerosispart1updateddiseaseclassificationanddiseasemodifyingtherapyuseinspecificcircumstances
‡A
CME/CNE Article: A Framework of Care in Multiple Sclerosis, Part 1: Updated Disease Classification and Disease-Modifying Therapy Use in Specific Circumstances
‡9
1
|
|
919
|
|
|
‡a
comprehensivesystematicreviewsummarydiseasemodifyingtherapiesforadultswithmultiplesclerosisreportoftheguidelinedevelopmentdisseminationandimplementationsubcommitteeoftheamericanacademyofneurology
‡A
Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
‡9
1
|
|
919
|
|
|
‡a
correctiontothesequenceofdiseasemodifyingtherapiesinrelapsingmultiplesclerosissafetyandimmunologicconsiderations
‡A
Correction to: The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations.
‡9
1
|
|
919
|
|
|
‡a
cryptococcalmeningitisafterfingolimoddiscontinuationinapatientwithmultiplesclerosis
‡A
Cryptococcal meningitis after fingolimod discontinuation in a patient with multiple sclerosis
‡9
1
|
|
919
|
|
|
‡a
diseasemodifyingtherapiesfornonrelapsingmultiplesclerosiscostsandbenefitsofmedicalintervention
‡A
Disease-modifying therapies for nonrelapsing multiple sclerosis: Costs and benefits of medical intervention
‡9
1
|
|
919
|
|
|
‡a
earlyrelapsingmultiplesclerosis
‡A
Early Relapsing Multiple Sclerosis
‡9
1
|
|
919
|
|
|
‡a
evaluationofanovelpreferenceassessmenttoolforpatientswithmultiplesclerosis
‡A
Evaluation of a Novel Preference Assessment Tool for Patients with Multiple Sclerosis
‡9
1
|
|
919
|
|
|
‡a
expandingspectrumofopportunisticinfectionsassociatedwithdimethylfumarate
‡A
Expanding spectrum of opportunistic infections associated with dimethyl fumarate
‡9
1
|
|
919
|
|
|
‡a
identificationandvalidationofclinicallymeaningfulbenchmarksinthe12itemmultiplesclerosiswalkingscale
‡A
Identification and validation of clinically meaningful benchmarks in the 12-item Multiple Sclerosis Walking Scale
‡9
1
|
|
919
|
|
|
‡a
intramedullaryspinalcordmetastasisfromsalivaryductalcarcinomaoftheparotidglandmimickingtransversemyelitisinapatientwithradiologicallyisolatedsyndrome
‡A
Intramedullary spinal cord metastasis from salivary ductal carcinoma of the parotid gland mimicking transverse myelitis in a patient with radiologically isolated syndrome
‡9
1
|
|
919
|
|
|
‡a
overviewandsafetyoffingolimodhydrochlorideuseinpatientswithmultiplesclerosis
‡A
Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis
‡9
1
|
|
919
|
|
|
‡a
practiceguidelinerecommendationssummarydiseasemodifyingtherapiesforadultswithmultiplesclerosisreportoftheguidelinedevelopmentdisseminationandimplementationsubcommitteeoftheamericanacademyofneurology
‡A
Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
‡9
1
|
|
919
|
|
|
‡a
stateofmultiplesclerosiscurrentinsightintothepatienthealthcareproviderrelationshiptreatmentchallengesandsatisfaction
‡A
The state of multiple sclerosis: current insight into the patient/health care provider relationship, treatment challenges, and satisfaction
‡9
1
|
|
919
|
|
|
‡a
rehabilitationinmultiplesclerosiscommentaryontherecentaansystematicreview
‡A
Rehabilitation in multiple sclerosis: Commentary on the recent AAN systematic review
‡9
1
|
|
919
|
|
|
‡a
sequenceofdiseasemodifyingtherapiesinrelapsingmultiplesclerosissafetyandimmunologicconsiderations
‡A
The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations
‡9
1
|
|
919
|
|
|
‡a
americanacademyofneurologystop5choosingwiselyrecommendations
‡A
The American Academy of Neurology's top five Choosing Wisely recommendations
‡9
1
|
|
919
|
|
|
‡a
summaryofcomprehensivesystematicreviewrehabilitationinmultiplesclerosisreportoftheguidelinedevelopmentdisseminationandimplementationsubcommitteeoftheamericanacademyofneurology
‡A
Summary of comprehensive systematic review: Rehabilitation in multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology
‡9
1
|
|
919
|
|
|
‡a
splenicmarginalzonelymphomaanindolentmalignancyleadingtothedevelopmentofneurolymphomatosis
‡A
Splenic marginal zone lymphoma: An indolent malignancy leading to the development of neurolymphomatosis
‡9
1
|
|
946
|
|
|
‡a
b
‡9
1
|
|
996
|
|
|
‡2
ISNI|0000000067406997
|
|
996
|
|
|
‡2
SUDOC|252372085
|
|
996
|
|
|
‡2
PLWABN|9810636308605606
|
|
996
|
|
|
‡2
ISNI|0000000022742882
|
|
996
|
|
|
‡2
LC|n 93003936
|
|
996
|
|
|
‡2
DNB|1227480717
|
|
996
|
|
|
‡2
LC|no2014014147
|
|
996
|
|
|
‡2
SUDOC|183448847
|
|
996
|
|
|
‡2
DNB|1158088477
|
|
996
|
|
|
‡2
ERRR|12293829
|
|
996
|
|
|
‡2
ISNI|0000000390648478
|
|
996
|
|
|
‡2
SUDOC|230220606
|
|
996
|
|
|
‡2
NUKAT|n 2009096026
|
|
996
|
|
|
‡2
NDL|00453410
|
|
996
|
|
|
‡2
LC|no2009187511
|
|
996
|
|
|
‡2
ISNI|0000000118772568
|
|
996
|
|
|
‡2
DNB|135349125
|
|
996
|
|
|
‡2
J9U|987007323639905171
|
|
996
|
|
|
‡2
ISNI|0000000073823842
|
|
996
|
|
|
‡2
LC|nb2011000479
|
|
996
|
|
|
‡2
LC|nb2011012225
|
|
996
|
|
|
‡2
J9U|987008916182305171
|
|
996
|
|
|
‡2
ISNI|0000000084531298
|
|
996
|
|
|
‡2
J9U|987007449402505171
|
|
996
|
|
|
‡2
NLA|000035650404
|
|
996
|
|
|
‡2
LC|n 98095236
|
|
996
|
|
|
‡2
ISNI|0000000110568634
|
|
996
|
|
|
‡2
SUDOC|034905324
|
|
996
|
|
|
‡2
BIBSYS|12069065
|
|
996
|
|
|
‡2
PLWABN|9810547597405606
|
|
996
|
|
|
‡2
SUDOC|158488164
|
|
996
|
|
|
‡2
NTA|380588773
|
|
996
|
|
|
‡2
BNF|16621095
|
|
996
|
|
|
‡2
LC|n 88611445
|
|
996
|
|
|
‡2
SELIBR|341855
|
|
996
|
|
|
‡2
LC|n 81047606
|
|
996
|
|
|
‡2
LC|no 95015952
|
|
996
|
|
|
‡2
NKC|jn20020717799
|
|
996
|
|
|
‡2
NTA|072461292
|
|
996
|
|
|
‡2
NSK|000639824
|
|
996
|
|
|
‡2
PLWABN|9810661414905606
|
|
996
|
|
|
‡2
NUKAT|nx2022586719
|
|
996
|
|
|
‡2
J9U|987012503136405171
|
|
996
|
|
|
‡2
ISNI|0000000114456779
|
|
996
|
|
|
‡2
LC|nb2017022265
|
|
996
|
|
|
‡2
J9U|987007449202005171
|
|
996
|
|
|
‡2
DNB|172171083
|
|
996
|
|
|
‡2
NUKAT|n 2018046639
|
|
996
|
|
|
‡2
ISNI|0000000036717733
|
|
996
|
|
|
‡2
NII|DA01180713
|
|
996
|
|
|
‡2
CAOONL|ncf10129258
|
|
996
|
|
|
‡2
SUDOC|184128226
|
|
996
|
|
|
‡2
NSK|000062784
|
|
996
|
|
|
‡2
ISNI|0000000062945609
|
|
996
|
|
|
‡2
SZ|122108000
|
|
996
|
|
|
‡2
DNB|1104286327
|
|
996
|
|
|
‡2
DBC|87097969538452
|
|
996
|
|
|
‡2
NSK|000615540
|
|
996
|
|
|
‡2
LC|no2009140244
|
|
996
|
|
|
‡2
LC|nb2008019790
|
|
996
|
|
|
‡2
CAOONL|ncf11168204
|
|
996
|
|
|
‡2
NUKAT|n 2012265883
|
|
996
|
|
|
‡2
B2Q|0000473548
|
|
996
|
|
|
‡2
DNB|1057808989
|
|
996
|
|
|
‡2
NUKAT|n 2022067279
|
|
996
|
|
|
‡2
ISNI|000000011797693X
|
|
996
|
|
|
‡2
LC|no2010115627
|
|
996
|
|
|
‡2
ISNI|0000000077922776
|
|
996
|
|
|
‡2
LC|no2012136921
|
|
996
|
|
|
‡2
ISNI|0000000099105128
|
|
996
|
|
|
‡2
DNB|1028245114
|
|
996
|
|
|
‡2
DNB|129573701
|
|
996
|
|
|
‡2
NKC|mub2017951678
|
|
996
|
|
|
‡2
DNB|124165885
|
|
996
|
|
|
‡2
LC|n 94800289
|
|
996
|
|
|
‡2
ISNI|000000006634283X
|
|
996
|
|
|
‡2
ISNI|0000000115083716
|
|
996
|
|
|
‡2
LC|n 83829126
|
|
996
|
|
|
‡2
ISNI|0000000026909563
|
|
996
|
|
|
‡2
BNF|13564854
|
|
996
|
|
|
‡2
LC|nb2014011069
|
|
996
|
|
|
‡2
LC|nb2009000633
|
|
996
|
|
|
‡2
JPG|500008432
|
|
996
|
|
|
‡2
LC|n 90646876
|
|
996
|
|
|
‡2
ICCU|CUBV085437
|
|
996
|
|
|
‡2
CAOONL|ncf10673814
|
|
996
|
|
|
‡2
BNC|981058608205506706
|
|
996
|
|
|
‡2
NLA|000035377373
|
|
996
|
|
|
‡2
LC|no2010115628
|
|
996
|
|
|
‡2
ISNI|0000000114642096
|
|
996
|
|
|
‡2
NDL|00558064
|
|
996
|
|
|
‡2
LC|n 84038756
|
|
996
|
|
|
‡2
PTBNP|1461046
|
|
996
|
|
|
‡2
BIBSYS|90286509
|
|
996
|
|
|
‡2
BIBSYS|90834795
|
|
996
|
|
|
‡2
ISNI|0000000078718531
|
|
996
|
|
|
‡2
NYNYRILM|234147
|
|
996
|
|
|
‡2
BNF|15077766
|
|
996
|
|
|
‡2
LC|n 2023180702
|
|
996
|
|
|
‡2
NTA|175529612
|
|
996
|
|
|
‡2
DNB|1146311699
|
|
996
|
|
|
‡2
NUKAT|n 2005119151
|
|
996
|
|
|
‡2
BIBSYS|90110691
|
|
996
|
|
|
‡2
W2Z|1488830535978
|
|
996
|
|
|
‡2
ISNI|0000000084329903
|
|
996
|
|
|
‡2
NTA|155684272
|
|
996
|
|
|
‡2
DNB|1165800713
|
|
996
|
|
|
‡2
ISNI|0000000032305651
|
|
996
|
|
|
‡2
SUDOC|243094760
|
|
996
|
|
|
‡2
NKC|jx20110825008
|
|
996
|
|
|
‡2
ISNI|000000050133355X
|
|
996
|
|
|
‡2
BNF|15094158
|
|
996
|
|
|
‡2
NII|DA03346544
|
|
996
|
|
|
‡2
PLWABN|9810554642705606
|
|
996
|
|
|
‡2
LC|nr 96009089
|
|
996
|
|
|
‡2
LC|nb 97091810
|
|
996
|
|
|
‡2
BIBSYS|1535375968934
|
|
996
|
|
|
‡2
ISNI|0000000119689475
|
|
996
|
|
|
‡2
J9U|987007386323105171
|
|
996
|
|
|
‡2
LC|nb2009001206
|
|
996
|
|
|
‡2
ISNI|0000000458511030
|
|
996
|
|
|
‡2
ISNI|0000000436245018
|
|
996
|
|
|
‡2
NKC|jo20241227751
|
|
996
|
|
|
‡2
SUDOC|26798166X
|
|
996
|
|
|
‡2
NUKAT|n 2012251524
|
|
996
|
|
|
‡2
LC|n 2012054116
|
|
996
|
|
|
‡2
J9U|987007369731705171
|
|
996
|
|
|
‡2
LC|nb2011016697
|
|
996
|
|
|
‡2
SIMACOB|61107555
|
|
996
|
|
|
‡2
BNF|17981041
|
|
996
|
|
|
‡2
LC|nb2003023577
|
|
996
|
|
|
‡2
LC|n 90607116
|
|
996
|
|
|
‡2
SUDOC|034056068
|
|
996
|
|
|
‡2
ISNI|0000000120801495
|
|
996
|
|
|
‡2
ISNI|0000000051654822
|
|
996
|
|
|
‡2
NII|DA02600916
|
|
996
|
|
|
‡2
J9U|987007351904905171
|
|
996
|
|
|
‡2
LC|no2008189523
|
|
996
|
|
|
‡2
LC|no2003089214
|
|
996
|
|
|
‡2
ISNI|0000000071512266
|
|
996
|
|
|
‡2
NII|DA02844535
|
|
996
|
|
|
‡2
NTA|126891516
|
|
996
|
|
|
‡2
NUKAT|n 2022072620
|
|
996
|
|
|
‡2
DNB|1047356929
|
|
996
|
|
|
‡2
NUKAT|n 2006072724
|
|
996
|
|
|
‡2
CAOONL|ncf11210540
|
|
996
|
|
|
‡2
SUDOC|151080313
|
|
996
|
|
|
‡2
LC|n 50080395
|
|
996
|
|
|
‡2
NUKAT|n 00094191
|
|
996
|
|
|
‡2
LC|n 78097051
|
|
996
|
|
|
‡2
LNB|LNC10-000183564
|
|
996
|
|
|
‡2
NTA|104762896
|
|
996
|
|
|
‡2
NII|DA04971646
|
|
996
|
|
|
‡2
LC|n 2003110534
|
|
996
|
|
|
‡2
DNB|128352078
|
|
996
|
|
|
‡2
J9U|987007421489505171
|
|
996
|
|
|
‡2
NUKAT|n 2015181788
|
|
996
|
|
|
‡2
NUKAT|n 2010133241
|
|
996
|
|
|
‡2
LIH|LNB:B0_t__z_;=CA
|
|
996
|
|
|
‡2
RERO|A012322120
|
|
996
|
|
|
‡2
SUDOC|078810167
|
|
996
|
|
|
‡2
BIBSYS|8019739
|
|
996
|
|
|
‡2
W2Z|9024008
|
|
996
|
|
|
‡2
BNF|14619140
|
|
996
|
|
|
‡2
ISNI|0000000038482069
|
|
996
|
|
|
‡2
LC|n 79032263
|
|
996
|
|
|
‡2
LC|n 2011033282
|
|
996
|
|
|
‡2
DNB|1345916736
|
|
996
|
|
|
‡2
ISNI|0000000109988535
|
|
996
|
|
|
‡2
CAOONL|ncf10678451
|
|
996
|
|
|
‡2
LC|no2020014448
|
|
996
|
|
|
‡2
LC|no2011176927
|
|
996
|
|
|
‡2
NKC|jo2018976156
|
|
996
|
|
|
‡2
KRNLK|KAC199700440
|
|
996
|
|
|
‡2
LC|n 91022384
|
|
996
|
|
|
‡2
ISNI|0000000079084067
|
|
996
|
|
|
‡2
LC|n 2004072714
|
|
996
|
|
|
‡2
SKMASNL|vtls004936168
|
|
996
|
|
|
‡2
N6I|vtls000035367
|
|
996
|
|
|
‡2
LC|n 82152592
|
|
996
|
|
|
‡2
DNB|141541911
|
|
996
|
|
|
‡2
LC|nb2017014800
|
|
996
|
|
|
‡2
NII|DA09435454
|
|
996
|
|
|
‡2
ISNI|0000000114732921
|
|
996
|
|
|
‡2
LC|n 85130732
|
|
996
|
|
|
‡2
NTA|072372397
|
|
996
|
|
|
‡2
RERO|A022789465
|
|
996
|
|
|
‡2
LC|nb2014007093
|
|
996
|
|
|
‡2
DNB|1157196586
|
|
996
|
|
|
‡2
NII|DA0177635X
|
|
996
|
|
|
‡2
ERRR|12293817
|
|
996
|
|
|
‡2
J9U|987007449799205171
|
|
996
|
|
|
‡2
ISNI|0000000064745213
|
|
996
|
|
|
‡2
LNB|LNC10-000094990
|
|
996
|
|
|
‡2
ISNI|0000000378727034
|
|
996
|
|
|
‡2
RERO|A003319994
|
|
996
|
|
|
‡2
LC|n 84001300
|
|
996
|
|
|
‡2
RERO|A013068432
|
|
996
|
|
|
‡2
NII|DA17816657
|
|
996
|
|
|
‡2
DNB|12213141X
|
|
996
|
|
|
‡2
CAOONL|ncf11023870
|
|
996
|
|
|
‡2
NLR|RU NLR AUTH 770126786
|
|
996
|
|
|
‡2
ISNI|0000000498396903
|
|
996
|
|
|
‡2
ISNI|0000000498396276
|
|
996
|
|
|
‡2
SUDOC|119978407
|
|
996
|
|
|
‡2
DNB|1252097131
|
|
996
|
|
|
‡2
DNB|1222928051
|
|
996
|
|
|
‡2
BNC|981061202166406706
|
|
996
|
|
|
‡2
ISNI|0000000033357920
|
|
996
|
|
|
‡2
DNB|136495389
|
|
996
|
|
|
‡2
DNB|172171091
|
|
996
|
|
|
‡2
ISNI|0000000119493317
|
|
996
|
|
|
‡2
J9U|987007400188505171
|
|
996
|
|
|
‡2
ISNI|0000000039380910
|
|
996
|
|
|
‡2
J9U|987007320550505171
|
|
996
|
|
|
‡2
ISNI|0000000053871089
|
|
996
|
|
|
‡2
BIBSYS|1634281488371
|
|
996
|
|
|
‡2
LC|n 84072686
|
|
996
|
|
|
‡2
ISNI|0000000063294852
|
|
996
|
|
|
‡2
BIBSYS|90168966
|
|
996
|
|
|
‡2
LC|n 84150102
|
|
996
|
|
|
‡2
NYNYRILM|257763
|
|
996
|
|
|
‡2
ISNI|0000000051497767
|
|
996
|
|
|
‡2
DE633|pe30093746
|
|
996
|
|
|
‡2
LC|n 2002103407
|
|
996
|
|
|
‡2
NII|DA02323430
|
|
996
|
|
|
‡2
NYNYRILM|257764
|
|
996
|
|
|
‡2
NUKAT|n 2008044085
|
|
996
|
|
|
‡2
LC|nb2011017249
|
|
996
|
|
|
‡2
SZ|118514091
|
|
996
|
|
|
‡2
LC|no2013134389
|
|
996
|
|
|
‡2
ISNI|0000000082349193
|
|
996
|
|
|
‡2
LC|n 2013014445
|
|
996
|
|
|
‡2
SUDOC|072477652
|
|
996
|
|
|
‡2
LC|no 99047482
|
|
996
|
|
|
‡2
ISNI|0000000021487621
|
|
996
|
|
|
‡2
DNB|1027582656
|
|
996
|
|
|
‡2
ISNI|000000008404406X
|
|
996
|
|
|
‡2
LC|no2003117012
|
|
996
|
|
|
‡2
N6I|vtls001359510
|
|
996
|
|
|
‡2
SUDOC|181385619
|
|
996
|
|
|
‡2
LC|nb 98046421
|
|
996
|
|
|
‡2
ISNI|0000000117332632
|
|
996
|
|
|
‡2
LC|nr 95032425
|
|
996
|
|
|
‡2
BIBSYS|1498562806210
|
|
996
|
|
|
‡2
J9U|987007321802305171
|
|
996
|
|
|
‡2
NTA|357160460
|
|
996
|
|
|
‡2
DNB|1175589020
|
|
996
|
|
|
‡2
RERO|A022861603
|
|
996
|
|
|
‡2
ISNI|0000000076740129
|
|
997
|
|
|
‡a
0 0 lived 0 0
‡9
1
|
|
998
|
|
|
‡a
Jones, David E.
‡c
(medycyna).
‡2
NUKAT|n 2021144679
‡3
title: (0.97, 'comprehensivesystematicreviewsummarydiseasemodyfingtherapiesforadultswithmultiplesclerosisreportoftheguidelinedevelopmentdisseminationandimplementationsubcommitteeofamericanacademyofneurology', 'comprehensivesystematicreviewsummarydiseasemodifyingtherapiesforadultswithmultiplesclerosisreportoftheguidelinedevelopmentdisseminationandimplementationsubcommitteeoftheamericanacademyofneurology')
‡3
viafid
|
